Primary inoperable or advanced non-small cell lung cancer
Conditions
Interventions
Serious adverse reaction group:Liquid biopsy or puncture biopsy
hyperprogressive group:Liquid biopsy or puncture biopsy
No serious adverse reactions or no super-progression group:Liquid biopsy or puncture biopsy
Sponsors
The General Hospital of the People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Able to provide written informed consent, and understand and agree to follow the research requirements; 2. Men or women over 18 years old; 3. Histopathologically diagnosed as the following cancer types, and received corresponding treatment: (1) Newly treated inoperable or advanced NSCLC patients: driver gene-negative lung adenocarcinoma; PD-1 monotherapy/PD-1 combined with pemetrexed + platinum therapy; lung squamous cell carcinoma: PD-1 Monotherapy/PD-1 combined with taxane + platinum therapy; (2) Newly treated SCLC (limited/extensive) patients: receive PD-L1 combined with etoposide + platinum therapy; (3) Metastatic esophageal squamous cell carcinoma: receive PD-1 combined with taxane/fluorouracil+platinum in the initial treatment or in the later line; (4) Metastatic urothelial carcinoma: receive PD-1 combined with taxane/gemcitabine+platinum for initial treatment or later line; (5) Advanced gastric cancer: receive PD-1/L1 combined with taxane/fluorouracil+platinum in the initial treatment or in the later line; (6) Advanced colorectal cancer: receive PD-1/L1 combined with FOLFOX/XELOX for initial treatment or later line; (7) Advanced cholangiocarcinoma: receive PD-1/L1 combined with taxane + platinum in the initial treatment or in the later line; (8) Advanced soft tissue sarcoma: receive PD-1/L1 single agent/PD-1/L1 combined with axitinib in the initial treatment or in the later line; 4. ECOG performance status = 6 months; 7. The patient must have sufficient organ function, and the following laboratory test values ??are required 7 days before treatment: (1) Absolute neutrophil count (ANC) >=1.5x10^9/L, platelets >=100x10^9/L, hemoglobin >=90g/L; (2) Remarks: The patient must not receive blood transfusion or growth factor support within 14 days before blood sample collection; (3) International normalized ratio (INR) or prothrombin time <= 1.5xULN; (4) Activated partial thromboplastin time (aPTT)<=1.5xULN; (5) Serum total bilirubin<=1.5xULN (patients with Gilbert syndrome can be enrolled if total bilirubin <3xULN); (6) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5xULN, if the patient has liver metastases, this standard is AST and ALT <= 5xULN.
Exclusion criteria
Exclusion criteria: 1. The patient has received blood transfusion within three months; 2. The patient has immune system deficiency; 3. Pregnant patients; 4. Patients with alcohol or drug addiction; 5. Other researchers believe that it may affect the experimental results or be unethical.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor growth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| time to progress; | — |
Countries
China
Contacts
Public ContactHu Yi
PLA General Hospital
Outcome results
None listed